Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Inhibitors of the enzyme acetylcholinesterase (AChE) are presently used as long-term symptomatic treatments for patients with Alzheimer disease (AD), as they enhance central levels of synaptic acetylcholine. The accumulation of evidence implicating AChE in the pathogenesis of AD raises the question of whether, in addition to their palliative actions, inhibitors of this enzyme are able to act as disease-modifying agents. In addition to their catalytic effects, there is a suggestion that AChE inhibitors may influence expression of AChE isoforms and increase expression of nicotinic receptors, both of which correlate with cognitive improvements in AD patients. The neuroprotective effect of nicotine, presumably mediated via nicotinic receptors, against beta-amyloid (Abeta) toxicity and its effect on amyloid precursor protein (APP) and Abeta production has previously been established. It has also been shown that AChE inhibitors influence APP processing and attenuate Abeta-induced toxicity via mechanisms including interruption of the production of Abeta, alteration of the levels of Abeta 1-50 and 1-52, and formation of the soluble form of APP. Some of these effects seem to occur independently of nicotinic receptors, however. If such experimental in vitro observations can be extrapolated into clinical neuroprotective properties, AChE inhibitors could positively modulate the disease course of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 2×
“In addition to detection of brain Ab, it is also possible to detect activation of microglia and inflammatory processes by PET.49 Figure 7 shows a S16 r 2006 Lippincott Williams & Wilkins schematic diagram of an amyloid plaque and associated pathogenic elements (and hence pharmacologic targets) that have been visualize…”
BackgroundOddo, S., Caccamo, A., Green, K. N., Liang, K., Tran, L., Chen, Y., Leslie, F. M., & LaFerla, F. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408500102 · Cited by 211 · cited 1×
“Recently it was also reported that in mice overexpressing both APP and tau, long-term treatment with nicotine caused increased tau phosphorylation in the brain.(22) It was suggested some years ago that smokers might have a lower level of amyloid in the brain.”
BackgroundYoudim, M. B. H., Fridkin, M., & Zheng, H. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.08.023 · Cited by 128
Cited by
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S. E., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 587
The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease
Schliebs, R., & Arendt, T. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0579-2 · Cited by 530
Cellular and molecular actions of Methylene Blue in the nervous system
Oz, M., Lorke, D. E., Hasan, M., & Petroianu, G. A. (2011) · Medicinal Research Reviews · doi:10.1002/med.20177 · Cited by 443
Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04134.x · Cited by 309
Metadata
- Authors
- Nordberg, A.
- Venue
- Alzheimer Disease & Associated Disorders
- Published
- 2006-04
- Volume
- 20
- Issue
- Supplement 1
- Pages
- S12-S18
- ISSN
- 0893-0341 (ISSN-L)
- OpenAlex
- W1998822036
- Cited by
- 134
- References
- 3
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease. https://app.cochat.ai/papers/10.1097/01.wad.0000213804.59187.2d
- The paper
- Nordberg, A. (2006). Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease. Alzheimer Disease & Associated Disorders. https://doi.org/10.1097/01.wad.0000213804.59187.2d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.